As shown in Fig. 1B, the fluorescence intensity of GFP-YAP1 was dramatically reduced by several compounds, among which Silmitasertib, a selective inhibitor of CK2 granted orphan drug designation by the FDA for cholangiocarcinoma and currently assessed in several other trials [24, 25], caused the strongest inhibitory effect. This evidence concerns the gene YAP1 and cholangiocarcinoma.